Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based therapy developed in Israel.” Cell Cure in its PR on this IND also listed three other key bullet points: “IND filed for Phase I/IIa dose escalation trial in patients …Read More
Trusted stem cell blog & resources